MERIT Fundamentals of iRECIST and Imaging Endpoints Webinar

Immunotherapeutic agents such as PD-1 inhibitors have demonstrated efficacy through many clinical trials. However, these agents have shown a novel response pattern termed pseudoprogression. iRECIST provides guidance for solid tumor response criteria in immunotherapy to accommodate possible pseudoprogression, which may occur in some subjects. In this presentation, MERIT discusses the rules and principles of iRECIST, imaging endpoints, and special considerations for using iRECIST response criteria.

[@MariaAuxiliadora-zk5fk]

Muito interessante, aguça minha curiosidade.